Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]
Wu X, Wang L, Qiu Y, Zhang B, Hu Z, Jin R. Int J Nanomedicine. 2017;12:8025–8034.On page 8025, the first affiliation was listed as “Department of Pediatrics, Union Hospital, Tongji Medical College, University of Science and Technology, Wuhan” however it should have been...
Enregistré dans:
Auteurs principaux: | Wu X, Wang L, Qiu Y, Zhang B, Hu Z, Jin R |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c87834b03b324e4780656bb26a09f54b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
par: Wu X, et autres
Publié: (2017) -
Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]
par: Soosay Raj TA, et autres
Publié: (2013) -
OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.
par: David Wroblewski, et autres
Publié: (2013) -
ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells.
par: Huan Wang, et autres
Publié: (2012) -
Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
par: Thomas X
Publié: (2012)